One thing I want to point out from yesterday was GC explaining the arbitrage between recap value and asset value as the motivation for Reg A+. While not everyone may agree this is the best plan, this confirms what I've been posting for some time, that we're not going to be raising Reg A+ capital at a valuation anywhere near what we are now. We're going to invite the market to invest in a company that oughta be worth more like $500M, meaning whatever capital we raise will create almost no additional dilution.

From what several presenters said, companies like Amarantus won't have much appeal to the generic retail investor because we're too complicated, but will use Reg A+ as a means to speak openly and directly to Wall Street, and to advocacy groups in the healthcare space.

The only other thing I'd note on rewatching, is the moment he comments about uplisting sooner rather than later depending on the sub success. The way he says it all is really interesting to me coupled with speculation by some of you, and that generally unnecessary PR about the valuation (still waiting on SEC filing) that they're bargaining with a partner as we speak.